Provided by Tiger Trade Technology Pte. Ltd.

AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF

25.29
-0.4754-1.84%
Volume:965
Turnover:24.46K
Market Cap:5.06M
PE:- -
High:25.43
Open:25.43
Low:25.28
Close:25.77
52wk High:27.94
52wk Low:22.63
Shares:200.00K
Float Shares:200.00K
Volume Ratio:1.17
T/O Rate:0.48%
Dividend:0.41
Dividend Rate:1.63%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly : Berenberg Raises to Buy from Hold; Raises Target Price to $1,400 from $1,220

THOMSON REUTERS
·
Yesterday

Lilly's Foundayo Grabs 30% Of New U.S. Orforglipron Patients, Chipping Away At Novo's Head Start

Options & Short Sell
·
Yesterday

US Oral Weight-Loss Drug Race Heats Up: Lilly's Foundayo Captures 30% of New Patients, Novo Nordisk's Early Lead Narrows

Stock News
·
Yesterday

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Yesterday

Scholar Rock downgraded to Equal Weight from Overweight at Barclays

TIPRANKS
·
Yesterday

Lilly Says Foundayo Has Captured over 30% of New US Patients on Oral Weight-Loss Drugs

Reuters
·
Yesterday

Kestra Medical Technologies Q1 Revenue Beats Estimates, Raises FY Revenue Outlook

Reuters
·
Yesterday

Eli Lilly Stock (LLY) Has 45% Upside, Says Citigroup

TIPRANKS
·
Yesterday

Novo Nordisk is Dropping Some Weight. it Still Faces a Bigger Challenge.

Dow Jones
·
Yesterday

Eli Lilly Exec Says Co NOW Has More than 30% Share in New Starts Within Oral Obesity Treatment Market -Morgan Stanley Conf

THOMSON REUTERS
·
Yesterday

Eli Lilly and Co Stock (LLY) Moved Up by 3.01% on Sep 14: Drivers Behind the Movement

TradingKey
·
Yesterday

Novo Nordisk A/S Series B Stock Rises Monday, Outperforms Market

Dow Jones
·
Yesterday

Dow Jones Top Company Headlines at 11 am ET: Microsoft Sets Limits for AI Models as Altman Details Control Risks | Dell's ...

Dow Jones
·
Sep 14

Novo Nordisk Kept at Hold as Analyst Maintains $47 Price Target Amid Strategic Uncertainty

TIPRANKS
·
Sep 14

Eli Lilly Announces R$ 0.2 Per Unit Dividend for 3Q 2026 BDRs

Reuters
·
Sep 14

Data Retention Terms Prompt Restraints on AI Model Use for Sensitive Operations

Deep News
·
Sep 14

Scholar Rock Says Its First Muscle-Targeted SMA Therapy Will Cost About $310,000 Annually

Reuters
·
Sep 14

Scholar Rock Holding Price Target Maintained with a $64.00/Share by Wedbush

Dow Jones
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

Novo Signals New Direction of Travel with Rebrand

Dow Jones
·
Sep 14